An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism

Jerod L. Ptacin(Sanofi (Turkey)), Marcos E. Milla(Johnson & Johnson (United States))
Nature Communications
August 9, 2021
Cited by 117


Related Papers